Celldex Therapeutics
CLDX
CLDX
164 hedge funds and large institutions have $2.44B invested in Celldex Therapeutics in 2023 Q4 according to their latest regulatory filings, with 33 funds opening new positions, 60 increasing their positions, 45 reducing their positions, and 12 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
14% more funds holding
Funds holding: 144 → 164 (+20)
5.71% more ownership
Funds ownership: 107.01% → 112.72% (+5.7%)
29% less call options, than puts
Call options by funds: $20.5M | Put options by funds: $28.8M
Holders
164
Holding in Top 10
6
Calls
$20.5M
Puts
$28.8M
Top Buyers
| 1 | +$80.5M | |
| 2 | +$56.1M | |
| 3 | +$41.4M | |
| 4 |
Morgan Stanley
New York
|
+$31.5M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$29.4M |
Top Sellers
| 1 | -$25.5M | |
| 2 | -$7.7M | |
| 3 | -$5.84M | |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$4.4M |
| 5 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$2.1M |